FOXA1 inhibits prostate cancer neuroendocrine differentiation
Authors:
Open Access
- 20 March 2017
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 36 (28) , 4072-4080
Abstract
Neuroendocrine prostate cancer (NEPC) has increasingly become a clinical challenge. The mechanisms by which neuroendocrine (NE) cells arises from prostate adenocarcinoma cells are poorly understood. FOXA1 is a transcription factor of the forkhead family that is required for prostate epithelial differentiation. In this study, we demonstrated that FOXA1 loss drives NE differentiation, demarcated by phenotypical changes and NEPC marker expressions. Mechanistically, this is mediated by FOXA1 binding to the promoter of interleukin 8 (IL-8), a chemokine previously shown elevated in NEPC, to directly inhibit its expression. Further, IL-8 upregulation activates the MAPK/ERK pathway, leading to ERK phosphorylation and enolase 2 (ENO2) expression. IL-8 knockdown or ERK inhibition, on the other hand, abolished FOXA1 loss-induced NE differentiation. Analysis of xenograft mouse models confirmed FOXA1 loss in NEPC tumors relative to its adenocarcinoma counterparts. Importantly, FOXA1 is downregulated in human NEPC tumors compared to primary and castration-resistant prostate cancers, and its expression is negatively correlated with that of ENO2. These findings indicate that FOXA1 transcriptionally suppresses IL-8, the expression of which would otherwise stimulate the MAPK/ERK pathway to promote NE differentiation of prostate cancer cells. Our data strongly suggest that FOXA1 loss may play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention.Keywords
This publication has 58 references indexed in Scilit:
- Neuroendocrine differentiation of prostate cancerAsian Journal of Andrology, 2013
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancerThe EMBO Journal, 2011
- Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonizationNature Medicine, 2011
- Reprogramming transcription by distinct classes of enhancers functionally defined by eRNANature, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer ProgressionCancer Cell, 2010
- Optimizing molecular signatures for predicting prostate cancer recurrenceThe Prostate, 2009
- Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas developmentGenes & Development, 2008
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008